Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/2292—Thymosin; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to the field of melanoma treatment.
• Melanoma is a malignant tumor of melanocytes which are found predominantly in skin but also in bowel and the eye (uveal melanoma). It is one of the rarer types of skin cancer but causes the majority of skin cancer related deaths.
• the treatment includes surgical removal of the tumor; adjuvant treatment; chemo- and immunotherapy, or radiation therapy. Of particular danger are metastases of the primary melanoma tumor.
• a method of treating melanoma or a metastasis thereof in a human patient in a combination therapy which comprises administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination comprising an alpha thymosin peptide and a kinase inhibitor.
• the present invention is directed to a method of treating melanoma or metastases thereof in human patients.
• the method involves administering a melanoma-treating effective combination to human melanoma patients, the combination comprising an alpha thymosin peptide and a kinase inhibitor.
• the combination further includes one or more additional agents to combat or treat melanoma.
• Alpha thymosin peptides comprise thymosin alpha 1 (TA1 ) peptides including naturally occurring TA1 as well as synthetic TA1 and recombinant TA1 having the amino acid sequence of naturally occurring TA1 , amino acid sequences substantially similar thereto, or an abbreviated sequence form thereof, and their biologically active analogs having substituted, deleted, elongated, replaced, or otherwise modified sequences which possess bioactivity substantially similar to that of TA1 , e.g., a TA1 derived peptide having sufficient amino acid homology with TA1 such that it functions in substantially the same way with substantially the same activity as TA1.
• Suitable dosages of the alpha thymosin peptide can be within the range of about 0.001- 10mg/kg/day.
• Thymosin alpha 1 and "TA 1” refer to peptides having the amino acid sequence disclosed in U.S. patent number 4,079, 137, the disclosure of which is incorporated herein by reference.
• Thymosin alpha 1 (TA1), initially isolated from Thymosin Fraction 5 (TF5), has been sequenced and chemically synthesized.
• TA1 is a 28 amino acid peptide with a molecular weight of 3108.
• Effective amounts of an alpha thymosin peptide are amounts which may be dosage units within a range corresponding to about 0.1-20 mg of TA1 , about 1-10 mg of TA1 , about 2-10 mg of TA1 , about 2-7 mg of TA1 , or about 3-6.5 mg of TA1 , and may comprise about 1.6, 3.2 or 6.4 mg of TA1 , or about 3.2 or 6.4 mg of TA1.
• a dosage unit may be administered once per day, or a plurality of times per day.
• Melanoma has various stages, which may include Stage 0, I, II, III and IV, as well as their respective subdivisions.
• the melanoma being treated is malignant metastatic melanoma.
• the melanoma being treated is stage I, stage II, stage III or stage IV.
• the melanoma being treated is stage M1a, M1 b or M1c melanoma.
• the alpha thymosin peptide is administered in a treatment regimen which includes administration to the patient of a kinase inhibitor.
• a treatment regimen which includes administration to the patient of a kinase inhibitor.
• kinase inhibitor include, without limitation, sorafenib.
• the method of the present invention comprises administering the alpha thymosin peptide along with administering a kinase inhibitor, during a course of the treatment regimen.
• the kinase inhibitor may be administered continuously (i.e., daily), multiple times per day, every other day, etc., and may be administered concurrently with the alpha thymosin peptide or separately therefrom during the treatment regimen, e.g., on the same day(s) as the alpha thymosin peptide or on different days during the course of the treatment regimen.
• the kinase inhibitor is administered in a dosage range of, e.g., about 10-2000 mg/day of administration, about 50-1000 mg/day, or about 50-800 mg/day.
• Daily dosages may be, e.g., about 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, etc.
• the combination further includes one or more additional agents to combat or treat melanoma.
• additional agents may be antineoplastic agents such as alkylating antineoplastic agents (AIkAA), which include, without limitation, dacarbazine (DTIC).
• Additional agent(s) of the combination such as alkylating antineoplastic agents (AIkAA) may be administered to patient within dosage ranges of, e.g., about 700-1300 mg/m 2 /day, about 800-1200 mg/m 2 /day, or at about 1000 mg/m 2 /day.
• AIkAA alkylating antineoplastic agents
• the various components of the combination may be administered concurrently with, or separately from, other components in a treatment regimen.
• the treatment regimen comprises a plurality of days, with the alpha thymosin peptide comprising thymosin alpha 1 (TA1), and the TA1 being administered to the patient during at least a portion of the treatment regimen at a dosage within a range of about 0.5-10 mg/day.
• the TA1 dosage is within a range of about 1.5-7 mg/day, or within a range of about 1.6-6.4 mg/day.
• the TA1 dosage is within a range of about 1.7-10 mg/day, about 1.7-7 mg/day, or about 3-7 mg/day.
• Exemplary dosages include about 1.6, 3.2 or 6.4 mg/day.
• the treatment regimen comprises administering the alpha thymosin peptide for a period of about 1-10 days, followed by about 1-5 days of non-administration of the alpha thymosin peptide; or the alpha thymosin peptide may be administered daily for about 3-5 days, followed by about 2-4 days of non-administration of the alpha thymosin peptide. Alternatively, the alpha thymosin peptide is administered daily for about 4 days, followed by about 3 days of non-administration of the alpha thymosin peptide.
• the invention comprises use of an alpha thymosin peptide and a kinase inhibitor in manufacture of a melanoma-treating effective pharmaceutical combination or medicament for use in a treatment regimen for treating melanoma or a metastasis thereof in a human melanoma patient.
• said medicament is for use in a treatment regimen which substantially excludes any immune-stimulating cytokine to said patient during said treatment regimen in an amount significant for treatment of melanoma or a metastasis thereof.
• said LDH blood level is below 475 IU/L.
• said LDH blood level is between 100 - 335 IU/L.
• One embodiment is the manufacture of a pharmaceutical combination including said alpha thymosin peptide, said combination further comprising a kinase inhibitor for use during a course of the treatment regimen, which alpha thymosin peptide and a kinase inhibitor may be administered separately or together.
• said kinase inhibitor is sorafenib.
• said medicament is for use in a treatment regimen which comprises a plurality of days, said alpha thymosin peptide comprises thymosin alpha 1 (TA1 ), and said TA1 is for use in administration to said patient during at least a portion of said treatment regimen at a dosage within a range of 0.5 - 10 mg/day.
• a treatment regimen which comprises a plurality of days
• said alpha thymosin peptide comprises thymosin alpha 1 (TA1 )
• said TA1 is for use in administration to said patient during at least a portion of said treatment regimen at a dosage within a range of 0.5 - 10 mg/day.
• said TA1 dosage is within a range of 1.5-7 mg/day.
• said TA1 dosage is 3.2 mg/day. [0031] According to one embodiment, said TA1 dosage is 6.4 mg/day.
• said alpha thymosin peptide is TA1 and said medicament is for use in a treatment regimen which comprises administration of TA1 daily for a period of about 1-10 days, followed by about 1-5 days of non-administration of said TA1.
• said TA1 is for use in administration daily for about 3-5 days, followed by about 2-4 days of non-administration of said TA1.
• said TA1 is for use in administration daily for about 4 days, followed by about 3 days non-administration of said TA1.
• the invention also relates to use of an alpha thymosin peptide and a kinase inhibitor in manufacture of a pharmaceutical combination for administration to a melanoma patient, wherein the alpha thymosin peptide and the kinase inhibitor may be administered separately or together, as well as to a kit comprising the alpha thymosin peptide, the kinase inhibitor, and optionally instructions for use in treatment of melanoma.
• Group 1 vehicle; Group 2: Sorafenib 80 mg/kg; Group 3: DITC 5 mg/kg; Group 4: TA-1 6 mg/kg; Group 5: TA-1 6 mg/kg + Sorafenib 80 mg/kg; Group 6: Sorafenib 80 mg/kg + DITC 5 mg/kg; and Group 7: Sorafenib 80 mg/kg + DITC 5mg/kg + TA-1 6 mg/kg.
• Tumor volume and body weight were measured every three days, and tumor weights were measured on Day 16 at the end of the study.
• Tumor measurement data showed that the mean tumor volumes of all treatment except Group 3 were statistically significantly smaller than that of Group 1 on Day 12 and Day 15. On Day 16, the mean tumor weights of all treatment groups were lower than Group 1.
• the Pl tw values of Group 2, Group 3, Group 4, Group 5, Group 6, and Group 7 were 85.76%, 28.41%, 43.35%, 70.41%, 86.34%, and 84.05% respectively, indicating effectiveness of all treatment regimens.
• the tumor model used in this study was valid as tumor growth was inhibited by DTIC, the positive control drug.
• Daily administration of test article TA-1 at 6 mg/kg was effective against the tumor growth. Sorafenib treatment was also effective towards the tumor inhibition in the model.
• TA-1 may be of value for enhancing the anti-tumor effect of a chemo-therapy and/or an immunotherapy designed for melanoma patients.
• the combination of TA-1 with a chemo-therapy may possess an additional value in reducing the toxic adverse effect of the chemotherapy.
• Thymosin Alpha-1 is an immunomodulator that may possess a potential anti-tumor activity.
• dacarbazine is the conventional chemotherapeutic drugs for the patients with melanoma.
• Sorafenib is an investigational drug for melanoma patients.
• the combined anti-tumor effect of TA-1 , Sorafenib, and DTIC was evaluated in the C57BL/6 mice subcutaneously implanted with B16 cells as a syngeneic melanoma model. Tumor growth was examined to explore the therapeutic potential of the combination for the treatment of melanoma. Body weights of host animals were measured to evaluate the toxic effect of the combination treatment.
• TA-1 (SciClone) was dissolved in PBS solution to achieve the proper dose concentration as indicated in Table 1.
• TA-1 solution was stored at 2-8 0 C and used up in one week.
• DTIC (Sigma) was initially dissolved in 0.01 N HCI and then diluted with PBS to 1 mg/mL. DTIC dosing solution was kept on ice, protected from light, and used within one day.
• Sorafenib (Shanghai Yingxuan Pharmaceutical Co., LTD) was dissolved in the mixture of Cremophor EL/ethanol (50:50; Sigma Cremophor EL, 95% ethyl alcohol) at 64 mg/mL (corresponding to 4-fold of the dosing concentration, Table 1 ), foil wrapped, and stored at room temperature. This 4 ⁇ stock solution was prepared fresh every 3 days. Final dosing solutions were prepared on the day of use by diluting the stock solution to 1 ⁇ with water. [0049] Table 1 : Dose Formulation
• Murine B16 melanoma cells were thawed from the stock of Cell Culture Center, lnsitutue of Basic Medical Sciences, Peking Union Medical College and Chinese Academy of Medical Sciences (PUMC&CAMS, Beijing, P.R.China). The tumor cells were adapted in C57BL/6 mice before use in the experiment. Please refer to Section 4.3.1 for details on cell adaptation.
• mice Forty-five male and forty-five female healthy, naive, C57BL/6 mice were received from the Institute of Laboratory Animal Science, CAMS, Beijing, P. R. China. The animals were six weeks old and weighed between 18 and 22 grams at the start of the study.
• PI TV (%) (TV vehicle - TVdrug treated)/ TV vehicle * 100 [0068]
• TW tumor weight
• PIT W (%) 100 x (TW vehicle - TW drug treated)/ TW vehicle
• Toxicity of all treatment regimens was evaluated with the body weights of the study animals along with the drug-induced animal deaths.
• the inhibition of body weight was calculated using Excel according to the equation below:
• Tumor Size [0078] Raw measurement data of tumor size are tabulated in Appendixes 1 -10. The calculated mean tumor volumes and statistical testing results of each treatment group versus the vehicle group are tabulated in the Tables 3-7.
• mice On Days 3 and 6 only a few mice had palpable tumors, and there was no statistical difference in tumor volume between vehicle control group and any treatment group.
• all surviving mice in the Groups 1-7 showed palpable tumors, and the mean tumor volume of each drug treatment group except Group 3 (DITC) was statistically significantly smaller than the vehicle control group (p ⁇ 0.05).
• the tumor model used in this study was valid as tumor growth was inhibited by positive control drug DTIC.
• Daily administration of test article TA-1 at 6 mg/kg was effective against the tumor growth.
• mean tumor volume in animals of Group 4 which received TA-1 treatment was significantly reduced by 50-60% in comparison to that of the vehicle control group.
• Tumor weights, which were measured on Day 16, were reduced by 43.35% in TA-1- treated animals.
• Sorafenib treatment resulted in 85.76% inhibition of tumor growth based on tumor weight measurement taken on Day 16.
• Sorafenib or Sorafenib+DITC were used in combination with TA-1 , there was no additional tumor inhibition.
• the sign "-" indicates that tumor does not reach a measurable size, while the sign 7 " indicates a dead animal.
• the sign "-" indicates that tumor does not reach a measurable size, while the sign 7 " indicates a dead animal.
• the sign 7 " indicates a dead animal.
• Appendix 15 Body weights (g) on Day 9
• the sign 7 " indicates a dead animal.
• a endix 17 Bod wei hts on Da 15
• the sign 7 " indicates a dead animal.
• TA1 is administered to melanoma patients in a treatment regimen at a dosage within a range of 0.5-10 mg/day.
• the melanoma patients also are treated with sorafenib at a dose level of 400 mg twice daily.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40755899

Family Applications (1)

Country Status (8)

Cited By (1)

Citations (1)

Family Cites Families (2)

• 2008
  • 2008-12-12 CN CN2008801268138A patent/CN101945664A/zh active Pending
  • 2008-12-12 AU AU2008335025A patent/AU2008335025A1/en not_active Abandoned
  • 2008-12-12 JP JP2010538181A patent/JP2011506473A/ja active Pending
  • 2008-12-12 US US12/747,438 patent/US20100267637A1/en not_active Abandoned
  • 2008-12-12 WO PCT/US2008/086545 patent/WO2009076587A1/en not_active Ceased
  • 2008-12-12 EP EP08858909A patent/EP2240194A4/en not_active Withdrawn
  • 2008-12-12 CA CA2708229A patent/CA2708229A1/en not_active Abandoned
  • 2008-12-15 AR ARP080105451A patent/AR069769A1/es not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events